Elutia Inc. (ELUT): Total Liabilities
$34.68M
As of 2025-12-31
$27.90M
As of 2026-06-30
-22.3%
3-year compound annual growth
-11.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.68M | -57.9% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $82.39M | +0.4% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $82.03M | +11.0% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $73.87M | +37.7% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $53.65M | -13.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $61.98M | +11.8% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $55.43M | n/a | 2021-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Elutia Inc. (ELUT) | 2025-12-31 | $34.68M | -57.9% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $43.53M | +5.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $16.50M | +15.8% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $45.63M | -3.1% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $295.48M | +119.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $14.12M | +22.9% |
Compare ELUT, PASG, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗